Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer.

Gut·2026
Same author

Exercise Capacity, Endothelial Function, Muscle Mass, and Strength in Pediatric Patients With Fontan Circulation.

CJC pediatric and congenital heart disease·2026
Same author

Human BMP4 mRNA Encapsulated in Lipid Nanoparticle for Bone and Articular Cartilage Repair in Aged Mice.

Journal of functional biomaterials·2026
Same author

Targeting TMED4 enhances CD8<sup>+</sup> T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.

Science advances·2026
Same author

Investigational New Drug-enabling studies in a human vessel-chip: Are we there yet?

Bioengineering & translational medicine·2026
Same author

Telomerase is induced during wound healing across species.

Skin health and disease·2026

関連する実験動画

Updated: Jun 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

スタチンは,血管新生に二相効果があります.

Michael Weis1, Christopher Heeschen, Alec J Glassford

  • 1Stanford University School of Medicine, Division of Cardiovascular Medicine, Stanford, Calif 94305, USA.

Circulation
|February 13, 2002
PubMed
まとめ

スタチンは,血管形成 (血管新生) に2つの効果を発揮する. 低用量はそれを促進し,高用量はコレステロールレベルとは関係なく,内皮細胞と血管成長因子に影響することによってそれを抑制します.

科学分野:

  • バイオケミストリー バイオケミストリー
  • 細胞生物学 細胞生物学
  • 薬理学 薬理学とは

背景:

  • スタチンは,HMG-CoA還元酵素阻害剤であり,コレステロールとイソプレノイド合成に影響を与えます.
  • イソプレノイドは,血管新生を含む様々な細胞機能を調節する.
  • 血管新生に対するセリバスタチンとアトルバスタチンの効果が調査されました.

研究 の 目的:

  • スタチンの血管新生に対する用量依存的効果を調査する.
  • これらの効果が脂質に依存しているかどうかを判断する.
  • スタチン媒介の血管新生におけるゲラニルゲラニルピロホスファートの役割を調査する.

主な方法:

  • 内皮細胞 (増殖,移動,分化) を用いたインビトロ研究.
  • 炎症誘発性血管新生のマウスモデルにおけるイン・ビボ研究.
  • ルイス肺がんモデルにおける腫瘍の成長と血管化の評価.

主要な成果:

  • スタチンの低濃度 (0.005-0.01μmol/L) は,内皮細胞機能を強化した.
  • 高濃度のスタチン (0.05-1μmol/L) は血管新生を阻害し,血管内皮成長因子 (VEGF) を減少させ,内皮アポトシスを増加させた.

さらに関連する動画

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

関連する実験動画

Last Updated: Jun 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

  • 高用量スタチンは,炎症誘発の血管新生とマウスの腫瘍増殖を抑制し,ジェラニルジェラニルピロホスファートによって効果は逆転した.
  • 結論:

    • HMG-CoA還元酵素抑制は,血管新生に二相性,用量依存的な効果を持っています.
    • スタチンの血管新生への影響は脂質に依存せず,内皮アポトーシスとVEGFシグナル伝達と関連しています.
    • 治療目的のスタチンの低用量はプロアンジオゲニックであり,高用量はアンジオスタティックであり,ゲラニル化タンパク質に影響を与える可能性があります.